Evidence map›Paper›PMID 34207861›Full record

ArticleCancers2021

Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?

Dana A M Mustafa, Lawlaw Saida, Diba Latifi, Leonoor V Wismans, Willem de Koning, Lona Zeneyedpour, Theo M Luider, Bernadette van den Hoogen, Casper H J van Eijck

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dana A M MustafaDepartment of Pathology, The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.ORCID 0000-0003-0644-078X
Lawlaw SaidaDepartment of Surgery, The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.
Diba LatifiDepartment of Surgery, The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.
Leonoor V WismansDepartment of Surgery, The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.ORCID 0000-0002-7009-7034
Willem de KoningClinical Bioinformatics Unit, Department of Pathology, The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.ORCID 0000-0002-4594-8423
Lona ZeneyedpourDepartment of Neurology, Clinical and Cancer Proteomics, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.
Theo M LuiderDepartment of Neurology, Clinical and Cancer Proteomics, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.
Bernadette van den HoogenDepartment of Viroscience, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.ORCID 0000-0003-1996-8559
Casper H J van EijckDepartment of Surgery, The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands.ORCID 0000-0002-9511-2157
Erasmus MC · NL

Funding

ZonMw 440.20.010.
6 · The paper itself

Abstract

Severe acute respiratory virus-2 (SARS-CoV-2) has spread globally leading to a devastating loss of life. Large registry studies have begun to shed light on the epidemiological and clinical vulnerabilities of cancer patients who succumb to or endure poor outcomes of SARS-CoV-2. Specific treatment for COVID-19 infections in cancer patients is lacking while the demand for treatment is increasing. Therefore, we explored the effect of Rintatolimod (Ampligen

Indexed as

cytokinesepithelial cancerous cellsinterferon signalingRintatolimodRNase LSARS-CoV-2Toll-like receptor 3

Identifiers

PMID34207861
PMCPMC8227153
OpenAlexW3169473462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.